Peijia Medical Limited
沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

VOLUNTARY ANNOUNCEMENT

COLLABORATION AND LICENSE AGREEMENT FOR TRANSCATHETER AORTIC VALVE REPLACEMENT PRODUCTS FOR THE TREATMENT OF AORTIC REGURGITATION WITH JENAVALVE TECHNOLOGY, INC.

This announcement is made by Peijia Medical Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the Group has recently entered into a collaboration and license agreement, a service agreement and a stock purchase agreement (collectively, the "**Agreements**") with JenaValve Technology, Inc. ("**JenaValve**" or the "**Licensor**"), a US-based medical device company. Pursuant to the Agreements, JenaValve has granted the Group an exclusive license regarding certain proprietary transcatheter aortic valve replacement ("**TAVR**") products (the "**Products**") for the treatment of aortic regurgitation ("**AR**") and aortic stenosis ("**AS**"). The Group is entitled to develop, manufacture, and commercialize such Products in the Greater China region and the Licensor agreed to provide services, assisting the Group to exploit the value of the Products within the region. The Group has also acquired certain shares of preferred stock of JenaValve, representing a minor equity investment in the Licensor.

AR is one of the most common types of aortic valve diseases. According to Frost & Sullivan, there were approximately 27.0 million patients worldwide and 3.9 million patients in China in 2020, suffering from AR. AR is also frequently seen in the presence of AS. However, the absence of annular and leaflet calcification in many AR patients makes anchoring and stabilizing the valve challenging. Currently, almost all TAVR products approved in China are only indicated for treating AS, but not for AR. There is no transfemoral TAVR product for treating AR approved in China. Therefore, there are huge unmet needs for TAVR products that can treat AR and that are minimally invasive.

JenaValve is a private company headquartered in Irvine, California, U.S., with manufacturing and assembly sites in Irvine, California, U.S. and Leeds, UK. The Trilogy™ Heart Valve System (the "**System**") developed by JenaValve is the first and the only transfemoral device of its kind to receive CE mark approval for the treatment of both severe symptomatic AR and AS. The System, with its proprietary locator technology, provides a unique system to position with the native leaflets. The locators clip onto the patient's native anatomy to secure valve stability. The valve's unique design also enables anatomical valve alignment, which facilitates future access to the coronary arteries and beneficial hemodynamics, both of which are significant clinical advantages for the treatment of AR. The System was also granted the Breakthrough Device Designation by the United States Food and Drug Administration.

The Company considers this transaction as an important step to strengthen its TAVR pipeline by adding first-in-class aortic valve regurgitation treatment system, and hopes to benefit more patients in China by expanding indications to AR with clinically proven minimally invasive options. Currently, the Company has two NMPA-approved TAVR products, including TaurusOne® and TaurusElite®, and three product candidates for treating severe AS, namely TaurusWave®, the non-implant based shock wave lithotripsy valvuloplasty system, TaurusNXT®, the non-glutaraldehyde crosslinking dry-tissue TAVR system and TaurusApex, the next generation polymer TAVR system. The transaction will enable the Company to have the most comprehensive TAVR pipeline covering major aortic valve diseases, compared to other players in China.

To the best knowledge of the Company, the transactions contemplated under the Agreements do not constitute notifiable transactions or connected transactions of the Company under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. To the best of the knowledge, information and belief of the Directors having made all reasonable enquiries, each of the ultimate beneficial owners of JenaValve is not a connected person of the Company and is an independent third party not connected with the Company and its connected persons.

SHAREHOLDERS AND POTENTIAL INVESTORS OF THE COMPANY TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the Board
Peijia Medical Limited
Dr. Yi Zhang
Chairman and Executive Director

Hong Kong, January 14, 2022

As of the date of this announcement, the Board comprises Dr. Yi Zhang, Mrs. Ping Ye Zhang and Ms. Hong Ye as executive Directors, Dr. Zhiyun Yu, Mr. Jifeng Guan, Mr. Fei Chen, Mr. Jun Yang as non-executive Directors, and Dr. Stephen Newman Oesterle, Mr. Robert Ralph Parks, Mr. Wai Ming Yip, and Mr. Huacheng Wei as independent non-executive Directors.